Thursday, December 13, 2012

Seeking Alpha: The Occultation Of Rigel Pharmaceuticals

Investors in Rigel Pharmaceuticals (RIGL) got another very much unwanted dose of bad (or at least confusing) data on Thursday, with disappointing OSKIRA-4 Phase 2 data on fostamatinib. While there are additional studies still under way and scenarios under which this drug could still make it, Rigel Pharmaceuticals is well on its way to being one of my worst biotech calls, and the risk on this stock is definitely running high.

Please read more here:
The Occultation Of Rigel Pharmaceuticals

No comments: